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ORIGINAL ARTICLE
Isolation and identification of an isomeric sildenafil analogue as an
adulterant in an instant coffee premix
Ahmad Yusri Mohd Yusop a,b, Linda Xiaoa and Shanlin Fu a
aCentre for Forensic Science, University of Technology Sydney, Ultimo, Australia; bPharmacy Enforcement Division, Ministry of
Health, Selangor, Malaysia
ABSTRACT
The proliferation of adulterated health foods and beverages in the market demands a com-
prehensive analytical strategy to identify the adulterants, particularly those of isomeric
phosphodiesterase 5 (PDE5) inhibitors. An instant coffee premix (ICP) purchased from an
online retailer was flagged for suspected adulteration through PDE5 inhibition assay. The ICP
was then analysed using suspected-target and non-targeted screenings of a liquid chroma-
tography-quadrupole time-of-flight mass spectrometry. Based on these findings, a PDE5
inhibitor initially assigned as compound X was isolated from the ICP by employing a liquid
chromatography-diode array detection before its structural elucidation with liquid chroma-
tography-ultraviolet (LC-UV) spectroscopy and nuclear magnetic resonance (NMR) spectro-
scopy. The suspected-target screening matched the protonated molecule ([MþH]þ)
precursor ion of compound X at m/z 499.2310 with two suspected analytes that are struc-
tural isomers of one another. The fragmentation patterns of compound X were comparable
to those analogues in the dithiocarbodenafil group through the non-targeted screening.
These findings, complemented by the LC-UV and NMR spectroscopy data, together with the
chromatographic separation of related structural isomers, conclude the identity of com-
pound X. To our best knowledge, this is the first study to report the presence of 3,5-dime-
thylpiperazinyl-dithiodesmethylcarbodenafil in an ICP sample.
KEY POINTS
 The herbal-based male sexual performance products’ lucrative market has instigated their
rampant adulteration, particularly with PDE5 inhibitors.
 The adulterated products may also contain analogues of the approved PDE5 inhibitors,
which usually passed into the market undetected as they are not included in the routine
targeted screening procedure.
 The present study detected, isolated, and identified an isomeric sildenafil analogue from
an instant coffee premix sample using rapid qualitative assay and comprehensive analy-
tical analysis.
 This paper highlighted the applicability of the established strategies for routine casework,
particularly in a forensic drug testing laboratory.
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Introduction
Herbal-based consumable products are widely per-
ceived as healthy and safe compared to modern
medicines [1]. Catchphrases such as all-natural, cer-
tified organic, and chemical-free are usually associ-
ated with these products to attract consumers.
Moreover, the dispersal of misleading information,
prominently through social networking media, along
with aggressive Internet marketing strategies, has
frequently deceived consumers [2]. Among the most
prevalent are health foods and beverages that adver-
tise to enhance male sexual performance [3]. These
products often stated on their labels to supposedly
made up of herbal aphrodisiacs such as Panax gin-
seng, Eurycoma longifolia, and Lepidium meyenii, to
name a few [4].
Regrettably, this lucrative market entices a wide-
spread adulteration, particularly with synthetic erec-
tile dysfunction drugs, namely phosphodiesterase 5
(PDE5) inhibitors [5]. Worse, these products usually
contain analogues of the approved drugs, viz. silde-
nafil, vardenafil, and tadalafil, which frequently
passed through undetected as they are not included
in the routine targeted screening procedure applied
by forensic drug testing laboratories [6]. An ana-
logue of PDE5 inhibitors is often synthesised by
minor modifications to the parent structure of the
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approved drugs; thus, altering their physical and
chemical properties [7]. Furthermore, some of these
analogues are structural isomers of one another,
making their identification a challenging task [8].
Clinical studies have shown that the approved
PDE5 inhibitors may produce common side effects
such as headache, flushing, dyspepsia, and abnormal
vision [9]. Besides, they may also cause severe drug-
drug interactions in patients on nitrates or a-block-
ers [10]. Contrarily, structural modifications on the
unapproved analogues may impact their absorption,
distribution, metabolism, and excretion, which could
result in unpredictable potency and side-effects [11].
For example, a sildenafil analogue, namely propoxy-
phenyl-thiohydroxyhomosildenafil, is 10-fold more
potent in inhibiting PDE5 enzyme compared to sil-
denafil [12]. Therefore, at the same dose, the ana-
logue is more likely to cause severe side effects
compared to sildenafil. Another analogue, acetilde-
nafil, has been reported to trigger ataxia, a side
effect that was never documented for PDE5 inhibi-
tors before [7]. This adulteration trend raises serious
concerns about food safety and public health, as
consumers are often unaware of the risks associated
with consuming such products [13]. A fatality case
associated with a sildenafil analogue, i.e. desmethyl-
carbodenafil [14], highlights the need for a compre-
hensive analytical strategy that may reveal the
presence of PDE5 inhibitors, particularly those of
the unapproved analogues.
In this study, an instant coffee premix (ICP) was
submitted to a comprehensive analytical procedure
with a pre-screening using PDE5 inhibition assay,
where it was flagged for suspected adulteration. The
ICP was then analysed to detect specific PDE5
inhibitors through suspected-target and non-targeted
screenings. A suspected PDE5 inhibitor, initially
assigned as compound X, was isolated from the ICP
to determine its identity.
Materials and methods
Chemicals and reagents
An ICP (SPL005) promoted as a male sexual per-
formance product was purchased from an estab-
lished online retailer based in Malaysia. Certified
reference materials (CRMs) of dithiodesmethylcar-
bodenafil, sildenafil impurity 12 (3,5-dimethylpiper-
azinyl-dithiodesmethylcarbodenafil), and sildenafil
impurity 18 (dithiopropylcarbodenafil) were pur-
chased from TLC Pharmaceutical Standards Ltd.
(Aurora, Ontario, Canada). Liquid chromatography
mass spectrometry (LC-MS) grade methanol and
acetonitrile were purchased from Chem-Supply Pty
Ltd. (Gillman, SA, Australia) while Sigma Aldrich
Pty Ltd. (Castle Hill, NSW, Australia) supplied the
LC-MS grade formic acid, analytical grade ammo-
nium formate, and deuterated chloroform (CDCl3).
Ultrapure water (18.2 MX-cm) was collected from a
Sartorius ariumVR pro ultrapure water system
(Goettingen, Germany) while LECO Australia Pty
Ltd. (Castle Hill) provided the QuEChERS extrac-
tion salt (EN 15662).
Screening of food products
Health foods and beverages marketed with claims to
enhance male sexual performance were pre-screened
using PDE5 inhibition assay [15]. In brief, the bio-
activity-based assay utilised a fluorescence polarisa-
tion technique to screen PDE5 inhibitors in foods
and beverages, by competing with fluorescein-labelled
cyclic-30,50-guanosine monophosphate (PDE5 sub-
strate) to bind to PDE5 enzyme. Suspected products
were flagged by their average PDE5 inhibition above
the threshold value of the blank ICP matrix.
The suspected products (high priority samples)
were then analysed to detect specific PDE5 inhibitors,
through suspected-target and non-targeted screenings,
with an Agilent Technologies (Santa Clara, CA, USA)
1290 Infinity II liquid chromatography (LC) system
coupled to an Agilent Technologies 6510 quadrupole
time-of-flight mass spectrometer (QTOF-MS) as
described previously [16]. Briefly, the suspected-target
screening employed a personal compound database
and library (PCDL), comprising 95 PDE5 inhibitors
and their analogues, providing extended coverage of
known analytes without the need for CRMs. A sus-
pected analyte was detected by comparing the accu-
rate mass of the precursor ion to the theoretical ones
in the library. The observed product ions were then
compared to the common fragmentation patterns of
target analytes, confirming the suspected analyte.
Isomeric analytes belonging to the same group of
PDE5 inhibitors, however, could not be distinguished
as they shared the same common fragmentation pat-
terns. The non-targeted screening was concomitantly
engaged to flag potentially novel PDE5 inhibitors
analogues based on the common fragmentation pat-
terns of target analytes; where the top-down and bot-
tom-up approaches were established to screen visible
and non-visible chromatographic peak, respectively.
The chromatographic separation was carried out
using a reverse-phase high-performance LC column
from Merck KGaA (Darmstadt, Germany)
ChromolithVR High-Resolution RP-18 end-capped
(100 4.6mm, 2.0 mm) with 10mmol/L ammonium
formate in ultrapure water (solvent A) and aceto-
nitrile (solvent B) as the binary mobile phase sys-
tem. Both solvents were acidified with 0.1% v/v
formic acid. The gradient elution was set as fol-
lows: 5% B for 0–1min, 5%–25% B for 1–2min,
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25%–50% B for 2–32min, 50%–95% B for 32–33min,
and 95% B for 33–34min at 0.4mL/min. The elution
was immediately returned to the initial gradient at
34.01min for 6min at 1mL/min with post-run
equilibration maintained at 0.4mL/min, 5min before
the next injection. The QTOF-MS was operated in
positive electrospray ionisation mode using a data-
dependent acquisition.
SPL005, in the form of an ICP, is promoted to
improve erectile function, prolong an erection, and
prevent premature ejaculation, among others. The
online advertisement also included a certificate of
analysis stating that the ICP is free from adulterants
such as sildenafil, vardenafil, and tadalafil. The
ingredients listed on the ICP sachet were as follows:
Eurycoma longifolia, Lepidium meyenii, arabica cof-
fee, goat’s milk, creamer, and brown sugar.
LC-UV analysis
The ultraviolet (UV) spectra were recorded on-line
during the chromatographic run from 200–400 nm,
with an Agilent Technologies 1290 Infinity LC
coupled to an Agilent Technologies 1290 Infinity
diode array detection (DAD), using the same chro-
matographic conditions as the screening of food
products, with the UV signal monitored at 356 nm.
Nuclear magnetic resonance (NMR) spectroscopy
The isolated compound X was dissolved in CDCl3
with 1H and 13C NMR spectra recorded using an
Agilent Technologies 500MHz NMR spectrometer
coupled to an Agilent Technologies 7510-AS auto-
mated NMR sample changer at room temperature.
The acquisition was performed at 499.86MHz
within 1 024 scans for 1H NMR and 125.70MHz
within 10 000 scans for 13C NMR. All the chemical
shifts were reported in d (ppm); measured relative
to CDCl3 (
1H d¼ 7.26, 13C d¼ 77.0). The coupling
constants (J values) were expressed in Hertz (Hz).
Standard solution preparation
Each CRM was prepared into a stock solution of
1mg/mL in methanol and stored at 4 C in the
dark. A working solution was freshly prepared at
3 mg/mL for each analysis from the stock solution by
further dilution in methanol.
Sample preparation
One-third of SPL005 contents, i.e. 8.5 g (25.5 g in
total per ICP sachet), were extracted using a modified
QuEChERS procedure described previously [17]. For
each extraction, 100mg of the sample was dissolved
in 5mL of acetonitrile and methanol (1:1, v/v),
sequentially via 1-min vortexing, 20-min sonication,
and 5-min centrifugation at 2500 g. The resulting
mixture was then transferred into a tube prefilled
with QuEChERS salt for extraction, by vortexing for
1min, followed by centrifuging for 5min at 2500 g.
The solutions from each extraction (85 extractions in
total) were filtered and combined into a round bot-
tom flask. The volume of the filtrate was subse-
quently reduced to 5mL using a rotary evaporator.
Isolation of compound X
Compound X was isolated from SPL005 through an
Agilent Technologies 1290 Infinity LC system fitted
with an end-capped high-performance LC column:
Nucleoshell RP 18 (100 4.6mm, 2.7mm) from
Macherey-Nagel GmbH & Co. KG (Duren, Germany).
The column compartment temperature was maintained
at 20 C with an injection volume of 20mL. The mobile
phases, consisting of solvent A (10mmol/L ammonium
formate in ultrapure water) and solvent B (acetonitrile),
were acidified with 0.1% v/v of formic acid. A shorter
gradient elution programme was devised specifically
for the isolation of compound X at 0.4mL/min as
follows: 5% B for 0–1min, 5%–45% B for 1–2min,
45%–65% B for 2–8min, 65%–95% B for 8–9min, and
95% B for 9–10min. The system was immediately
returned to the initial gradient with post-run equilibra-
tion maintained for 3min before the next injection.
The fraction of compound X was collected fol-
lowing a DAD at 356 nm using an Agilent
Technologies 1290 Infinity DAD. The procedure
was repeated a number of times to obtain enough
compound X for the LC-UV and NMR spectroscopy
analysis. The collected fractions were then combined
and placed under a gentle stream of nitrogen gas to
remove the residual solvents.
Data analysis
The qualitative and quantitative data of the
LC-QTOF-MS, LC-DAD, and LC-UV analyses were
processed through an Agilent Technologies Mass
Hunter workstation software version B.07.00, Mass
Hunter qualitative analysis software version B.07.00,
and PCDL manager software version B.04.00. A
Bruker (Billerica, MA, USA) TopSpin software ver-
sion 4.0.6 was applied to analyse the NMR data.
Results and discussion
Screening of SPL005
SPL005 was initially flagged for suspected adultera-
tion through PDE5 inhibition assay, where it
showed to inhibit the PDE5 enzyme [15]. An
LC-QTOF-MS analysis [16] later unveiled the
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presence of one unidentified peak, initially assigned
as compound X at 27.85min of the base peak chro-
matogram (BPC) (Figure 1A). The full-scan MS in
Figure 1B shows a protonated molecule ([MþH]þ)
at m/z 499.2310, suggesting a chemical formula of
C25H34N6OS2 with a mass error of 0.40 ppm. The
Figure 1. (A) Base peak chromatogram (BPC) of SPL005 with one unidentified peak, initially assigned as compound X; (B) full-
scan mass spectrometry (MS) with a protonated molecule ([MþH]þ) at m/z 499.2310 (also showing the matching scores of
the observed mass, isotopic abundance distribution, and isotopic spacing of compound X with C25H34N6OS2); (C) and (D) prod-
uct ion scan employing the non-targeted screening at m/z 343.0682 and m/z 371.0995; (E) and (F) common fragmentation
patterns shared by dithiodesmethylcarbodenafil and compound X at averaged collision energies (CEs).
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matching scores of the observed mass, isotopic abun-
dance distribution, and isotopic spacing for compound
X were also ascertained to be >80%. The suspected-
target screening [16] matched the [MþH]þ precursor
ion with two suspected analytes, i.e. 3,5-dimethylpiper-
azinyl-dithiodesmethylcarbodenafil and dithiopropyl-
carbodenafil, via the PCDL library.
In addition to this, the product ion scan employ-
ing the non-targeted screening [16] revealed the pres-
ence of two product ions corresponding to the
common fragmentation patterns shared by the
dithiocarbodenafil group of analogues, presented in
Figure 2 due to the cleavage of piperazine ring and
subsequent loss of ethene from the ethoxyphenyl
moiety. Figure 1C and D further display the product
ions’ signals at m/z 343.0682 and m/z 371.0995,
which aligned with the peak of compound X within
±20ppm mass error. Dithiodesmethylcarbodenafil
CRM, which represents the dithiocarbodenafil group
of analogues, shared the same common fragmenta-
tion patterns as compound X at averaged collision
energies, shown in Figure 1E and F.
These findings indicated that compound X belongs
to the dithiocarbodenafil group of analogues.
Figure 2. Proposed common fragmentation patterns shared by dithiocarbodenafil group of analogues.
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However, both of the suspected analytes are structural
isomers of one another. Besides, four other possible
structural isomers could be generated based on these
findings. Complementary technique such as LC-UV
and NMR spectroscopy would, therefore, be highly
valuable following analyte isolation and purification.
LC-DAD and LC-UV of compound X
Compound X (2mg) in the form of pale-yellow
solid was isolated from the LC-DAD and then ana-
lysed by employing LC-UV and NMR spectroscopy.
Figure 3 displays the UV spectrum of compound X
with maximum absorbance at 249, 284, and 357 nm,
similar to that of dithiodesmethylcarbodenafil. The
3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil
and dithiopropylcarbodenafil also exhibited similar
UV spectrum patterns, overlaid as a comparison.
NMR spectroscopy of compound X
Table 1 compiles the 1H and 13C NMR data of com-
pound X in comparison with the structurally related
PDE5 inhibitors, i.e. dithiodesmethylcarbodenafil [18],
3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil
[19], and dithiopropylcarbodenafil [20]. The 1H and
13C NMR signal assignments of compound X, as well
as 3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil
and dithiopropylcarbodenafil, were comparable to that
of dithiodesmethylcarbodenafil, except for the pipera-
zine ring environment at positions 24–31. Indeed, all
PDE5 inhibitors within the dithiocarbodenafil group
of analogues possess similar skeletal configurations at
positions 1–23, except for the different substitutes on
the piperazine ring. Compound X was, therefore, cha-
racterised based on this skeletal structure.
Supplementary Figure S1 shows the 1H NMR
spectrum of the isolated compound X. A broad sing-
let peak at 2.47 ppm was assigned to a methyl group
attached to a nitrogen atom at position H-29, based
on the 1H NMR signal of dithiodesmethylcarbodena-
fil [18]. The chemically equivalent protons of the
methine groups attached to the same nitrogen atom
at positions H-25 and H-27 are predicted to have
similar chemical shifts within the range of 2 to
3 ppm. Therefore, they were assigned at 2.47ppm
within the same broad singlet peak. Another chem-
ically equivalent protons of the methylene groups at
positions H-24 and H-28 are expected to produce
higher chemical shifts due to the diamagnetic anisot-
ropy effect from a nearby thiocarbonyl group com-
pared to those of H-25 and H-27 [18]. Therefore,
they were assigned at 3.60 and 3.70 ppm, taking into
account the axial and equatorial protons [21]. Finally,
the two methyl groups at positions H-30 and H-31
were assigned to two doublet peaks at 1.05 and
1.02 ppm, respectively. As well, the 13C NMR chemi-
cal shifts of compound X at positions C-29, C-30,
and C-31 were similar to those of 3,5-dimethylpipera-
zinyl-dithiodesmethylcarbodenafil, indicating the
presence of three methyl groups attached to the
piperazine ring. These results ruled out the possibility
of having an N-propylated linear chain group con-
nected to the piperazine ring of compound X.
Figure 3. Overlaid ultraviolet (UV) spectra of three structurally related phosphodiesterase 5 (PDE5) inhibitor standards at 1mg/
mL and compound X isolated from SPL005.
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Isolation and structural elucidation of compound X
through the LC-DAD and NMR spectroscopy are
rather challenging due to the complexity of the ICP
matrix, which typically contains multiple ingredients.
Furthermore, the low quantity of the adulterant, often
at trace levels relative to the matrix components,
demands a larger sample size to isolate sufficient
amounts of PDE5 inhibitor for different types of NMR
Table 1. 1H and 13C NMR data (d in ppm, J in Hz) of compound X and structurally related PDE5 inhibitors.
Dithiodesmethylcarbodenafil
3,5-dimethylpiperazinyl-
dithiodesmethylcarbodenafil Dithiopropylcarbodenafil Compound X
1H (dH) 13C (dC) 1H (dH) 13C (dC) 1H (dH) 13C (dC) 1H (dH) 13C (dC)
1 NA NA NA NA NA NA NA NA
2 NA NA NA NA NA NA NA NA
3 NA 146.2 NA 144.7 NA 146.2 NA 144.6
4 NA NA NA NA NA NA NA NA










7 NA 171.8 NA 171.6 NA 171.7 NA 170.2
8 NA 132.3 NA 131.8 NA 132.3 NA 132.2















































16 NA 118.5 NA 120.6 NA 118.4 NA 121.6
17 7.55
(1H, dd, 2.5, 8.0)
131.7 7.48
(1H, dd, 2.5, 8.0)
130.6 7.57
































22 NA 199.3 NA 196.6 NA 198.8 NA 198.1




































































Note: Positions 1–31 indicate either a hydrogen or carbon signal.
Abbreviations: s, singlet; brs, broad singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; NA: not applicable.The number of protons for each 1H NMR signals cannot be established due to the presence of unknown impurities in the isolated compound X.
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experiments. Nevertheless, based on the obtained 1H
and 13C NMR data, the identity of compound X could
still be inferred as the signal assignments comparable
to that of 3,5-dimethylpiperazinyl-dithiodesmethylcar-
bodenafil, particularly for the three methyl groups at
positions 29–31 of the piperazine ring.
Confirmation of compound X
The chemical structure of compound X was prima-
rily elucidated from the LC-QTOF-MS, LC-UV, and
NMR spectroscopy data. However, to confirm these
findings, three CRMs of structurally related PDE5
inhibitors, i.e. dithiodesmethylcarbodenafil, 3,5-dime-
thylpiperazinyl-dithiodesmethylcarbodenafil, and dithio-
propylcarbodenafil, were acquired to unambiguously
conclude the identity of compound X, if possible, based
on the chromatographic separation. Figure 4 shows an
overlaid BPCs of the three structurally related PDE5
inhibitor standards at 1mg/mL and compound X iso-
lated from SPL005. Dithiodesmethylcarbodenafil eluted
at 26.26min, followed by 3,5-dimethylpiperazinyl-
dithiodesmethylcarbodenafil and dithiopropylcarbode-
nafil at 27.78min and 29.46min, respectively. These
findings indicated that the structural isomers were sep-
arated down to a baseline level, ensuring the specificity
of each analyte.
Compound X, isolated from SPL005 eluted at
27.84min, within ±0.25min of the retention time of
3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil.
Based on this finding, the 1mg/mL standard solution
of 3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil
was spiked into the ICP sample solution at 1:10 v/v to
substantiate the identity of compound X. The BPC of
the spiked ICP showed only one peak at 27.80min,
similarly within ±0.25min of the retention time of the
CRM. These results, complemented by the previous
data, concluded the identity of compound X as
3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil. The
content of the adulterant was subsequently quantified
at 8.4mg per sachet of the ICP sample.
Conclusion
This study’s comprehensive analytical procedure has
identified an isomeric sildenafil analogue from an
ICP marketed to enhance male sexual performance.
Pre-screening with PDE5 inhibition assay and the fol-
lowing LC-QTOF-MS analysis revealed the presence
of a suspected compound X. However, the suspected-
target screening with an LC-QTOF-MS matched
compound X with two suspected analytes that are
structural isomers of one another. Compound X was,
therefore, isolated from the ICP using an LC-DAD
and then submitted to LC-UV and NMR spectros-
copy analysis. The UV spectrum, as well as the NMR
signals of compound X, closely matched to that of the
3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil.
The identity of compound X was finally concluded
by comparing its chromatographic separation with the
structurally related PDE5 inhibitors. For the identifica-
tion of structural isomers, baseline separation by way
of chromatography is superior as their full spectral
information are often indistinguishable, as demon-
strated by 3,5-dimethylpiperazinyl-dithiodesmethylcar-
bodenafil and dithiopropylcarbodenafil. To our
best knowledge, this is the first study to report an
adulterated ICP containing 3,5-dimethylpipera-
zinyl-dithiodesmethylcarbodenafil.
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